Cytokinetics
CYTK

Cytokinetics (CYTK) earnings history

Most recent quarter

Period end
Jun 30, 2026
EPS actual
−$1.50
EPS estimate
−$1.63
Revenue
$28.6M
Reported
Aug 6, 2026

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2026Aug 6, 2026−$1.63−$1.50+7.87%$28.6MSEC
Q1 2026May 5, 2026−$1.65−$1.67−1.07%$19.4MSEC
Q4 2025Feb 24, 2026−$1.56−$1.50+4.12%$17.8MSEC
Q3 2025Nov 5, 2025−$1.57−$2.55−62.36%$1.9MSEC
Q2 2025Aug 7, 2025−$1.43−$1.12+21.66%$66.8MSEC
Q1 2025May 6, 2025−$1.37−$1.36+0.69%$1.6MSEC
Q4 2024Feb 27, 2025−$1.19−$1.26−5.62%$16.9MSEC
Q3 2024Nov 7, 2024−$1.23−$1.36−10.16%$463,000.00SEC
Q2 2024Aug 8, 2024−$1.06−$1.31−23.98%$249,000.00SEC
Q1 2024May 8, 2024−$1.14−$1.33−16.29%$835,000.00SEC
Q4 2023Feb 27, 2024−$0.96−$1.38−43.97%$1.7MSEC
Q3 2023Nov 2, 2023−$0.74−$1.35−81.74%$378,000.00SEC
Q2 2023Aug 3, 2023−$1.14−$1.34−17.61%$867,000.00SEC
Q1 2023May 4, 2023−$1.20−$1.38−15.06%$4.6MSEC
Q4 2022Mar 1, 2023−$1.21−$1.45−20.22%$2.0MSEC
Q3 2022Nov 3, 2022−$1.16−$1.52−30.61%$2.5MSEC
Q2 2022Aug 4, 2022−$1.03−$0.23+77.66%$89.0MSEC
Q1 2022May 4, 2022−$0.94−$1.05−11.28%$1.1M
Q4 2021Feb 24, 2022−$0.85−$0.36+57.56%$55.6M
Q3 2021Nov 3, 2021−$0.78−$0.95−22.42%$5.4M

Quarterly revenue

Q3 2021
$5.4M
Q4 2021
$55.6M
Q1 2022
$1.1M
Q2 2022
$89.0M
Q3 2022
$2.5M
Q4 2022
$2.0M
Q1 2023
$4.6M
Q2 2023
$867,000.00
Q3 2023
$378,000.00
Q4 2023
$1.7M
Q1 2024
$835,000.00
Q2 2024
$249,000.00
Q3 2024
$463,000.00
Q4 2024
$16.9M
Q1 2025
$1.6M
Q2 2025
$66.8M
Q3 2025
$1.9M
Q4 2025
$17.8M
Q1 2026
$19.4M
Q2 2026
$28.6M

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.